

Rhino-Orbital Mucormycosis After Covid-19 In the Emergency Department

 Burak Çelik¹,  Halit Karakisa²,  Mehmet Kemal Emem³,  Bahadır Karaca⁴

¹Ministry of Health Kırşehir Provincial Health Directorate Kırşehir Training and Research Hospital, Kırşehir, Turkey.

²Istanbul Provincial Directorate of Health Istanbul Prof.Dr. Cemil Taşçıoğlu City Hospital, İstanbul, Turkey.

³Şanlıurfa Provincial Directorate of Health Şanlıurfa Balıklıgöl State Hospital, Şanlıurfa, Turkey.

⁴Republic of Turkey Ministry of Health İstanbul Provincial Health Directorate Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey.

Abstract

Rhino-orbital mucormycosis (ROM) is an acute and fulminant infection. The number of ROM cases developing after coronavirus disease 2019 (COVID-19) is increasing. A 62-year-old male patient was admitted to the emergency department in northern Syria complaining of new-onset vision loss, swelling, and severe swelling of the left eye. It was noted that a 3-day course of prednisolone 250 mg was given to treat COVID-19. We found that he had a history of diabetes mellitus (DM) for 10 years. Physical examination revealed ptosis, proptosis, and ocular movement restriction in all directions in the left eye. All other systemic examinations were normal. A cranial and orbital magnetic resonance imaging scan performed after hospitalization for further evaluation and treatment showed an increase in the density of the sphenoid, ethmoid, and frontal sinus walls in the left orbit. Despite antifungal and surgical treatment, the patient died on day 14. The use of steroids in treatment and the presence of concomitant DM are the main predisposing factors. The prognosis of this disease, which has a high mortality and morbidity, is adversely affected in geographic regions where health care is inadequate.

Keywords: COVID-19, emergency service, mucormycosis, rhino-orbital mucormycosis

Introduction

Rhino-orbital mucormycosis (ROM) is an acute and fulminant infection caused by Mucoraceae fungi and occurs in immunocompromised and diabetic patients¹. While the paranasal sinuses and nose are the primary sites of inoculation, these aggressive fungi can cause life-threatening infections in the orbit and brain through direct or hematogenous spread. Coronavirus disease 2019 (COVID-19 disease) affects T lymphocytes and causes immunosuppression lymphopenia. In addition, the presence of concomitant diseases such as diabetes mellitus (DM), the use of steroid therapy, and the use of other immunomodulatory drugs cause immunosuppression that predisposes these patients to opportunistic fungal infections^{2,3}. The coexistence of COVID-19 with invasive ROM is rarely reported in the literature, and diabetes mellitus is often cited as the major predisposing factor. In this case report, a rare case of ROM was reported that developed in a diabetic patient who received high-dose steroid therapy due to COVID-19 treatment.

Case Report

A 62-year-old male patient was admitted to the emergency department in northern Syria complaining of new-onset vision loss, pain, and severe swelling of the left eye. It was noted that he had received 10 days of inpatient treatment for COVID-19 thirty days ago. As part of the treatment, favipiravir, chloroquine, acetaminophen, and 3 days of prednisolone 250 mg were administered. The patient reported that he had had DM for 10 years. The patient's vital signs were stable on admission. Physical examination revealed ptosis, proptosis, and ocular movement restriction in all directions in the left eye (Image 1). All other systemic examinations were normal. A cranial and orbital magnetic resonance imaging scan performed after hospitalization for further evaluation and treatment showed an increase in the density of the sphenoid, ethmoid, and frontal sinus walls in the left orbit (Image 2). A biopsy which had taken from the patient showed *Rhizopus* spp. IV Amphotericin B was started for the treatment of ROM. Surgical treatment included exenteration of the left eye and sinus drainage. The patient died on day 14 due to multiorgan dysfunction.

Corresponding Author: Burak Çelik **e-mail:** burakcelik57@hotmail.com

Received: 12.11.2021 • **Revised:** 07.03.2022 • **Accepted:** 10.03.2022

DOI: 10.33706/jemcr.1072718

©Copyright 2020 by Emergency Physicians Association of Turkey - Available online at www.jemcr.com

Cite this article as: Çelik B, Karakisa H, Emem MK, Karaca B. Rhino-orbital mucormycosis after covid-19 in the emergency department. *Journal of Emergency Medicine Case Reports.* 2022;13(3): 76-78



Image 1. Photo of the patient: Face of the patient shows exophthalmos and ptosis in the left eye, nasal deviation to the right, left maxillofacial swelling and edema and right deviation of the vestibulum oris.




Image 2. Magnetic resonance images of the patient: As a result of mucormycosis; increased density in the left maxillary sinus, deviation of the nasal septum (A), increased density in area of the left parasphenoid and medial paraorbital (B), increased density in the left ethmoid sinus and exophthalmos in the left orbit (C), increased density in the left frontal sinus (D).

Discussion

ROM is a rare disease that is difficult to diagnose and has high mortality and morbidity. Immediate early diagnosis and treatment is lifesaving^{4,5}. Although a multidisciplinary approach is of great importance in improving prognosis, treatment approaches may vary depending on the conditions of the health care system. The current treatment modalities include pharmacological treatment following surgical intervention. But the current condition of the health care system in northern Syria from the perspective of resource scarcity and availability of current treatments makes the treatment of rare and deadly diseases more challenging.

DM and corticosteroid therapy are the most common risk factors in ROM cases that develop after COVID-19⁶. At the same time, medical treatments, hospitalization in the intensive care unit, and treatment with broad-spectrum antibiotics predispose COVID-19 patients to opportunistic fungal infections, which occur in 8% of patients^{7,8}. DM remains the most important risk factor in ROM after COVID-19^{9,6}. Besides, dexamethasone, hydrocortisone, and prednisolone are reported to be used in most cases that developed ROM. Although steroids are proven to be beneficial in COVID-19, cautious use is recommended because they cause hyperglycemia and monocytic and neutrophil dysfunction. The dose and duration of steroid treatment which may cause ROM remains uncertain in patients with Covid-19.

According to the European Mycosis Working Group guidelines, treatment success depends on the applicability of surgical techniques and the availability of antifungal therapies⁴. For the maximization of the survival rates a multidisciplinary team consisting of medical, surgical, radiological and laboratory specialities, and rapid diagnostic and therapeutic interventions are required. According to this guideline, the use of systemic liposomal amphotericin B along with early surgical debridement with clean margins is recommended as first-line therapy. The challenging decision of exenteration of the occupied orbit is recommended to remove the fungal load and to prevent cerebral involvement. In addition, intravenous isavuconazole or delayed-release tablet posaconazole are recommended but not Amphotericin B deoxycholate because of its toxicity. In assessing the postwar situation in northern Syria, we believe that the limited availability of the drugs, the lack of multidisciplinary approach and technical equipment for biopsy and surgical treatment negatively affect the prognosis.

Early diagnosis and treatment are very important for the prognosis of the disease¹⁰. In addition to physical examination findings, radiological imaging and knowledge of risk factors can be helpful for early diagnosis. Biopsy and detection of fungi in CSF or sputum are required for a definitive diagnosis. Evidence of nodular thickening or destruction of the bony walls of the paranasal sinuses and

the absence of an air-fluid level on imaging may be a sign of invasive opportunistic infection.

Conclusion

The number of ROM cases is increasing after COVID-19. The use of steroids in treatment and the presence of concomitant DM are the main predisposing factors. The prognosis of this disease, which has high mortality and morbidity, is adversely affected in geographic regions where health care is inadequate.

References

1. Gumral R., Yıldızoglu U., Saracli MA., Kaptan K., Tosun F., Yildiran ST. A case of rhinoorbital mucormycosis in a leukemic patient with a literature review from Turkey. *Mycopathologia* 2011;172: 397-405.
2. Oğuz H., Yılmaz Ö. Increasing cases of Orbital Mucormycosis in recent years. *Clinical and Experimental Ocular Trauma and Infection* 2021;3: 10-11.
3. Kaya O., Çavuş SA., Turhan Ö., Taşbakan Mİ., Pullukçu H., Ertuğrul MB., et al. Evaluation of patients with zygomycosis. *Turkish Journal of Medical Sciences* 2014;44: 476-483.
4. Cornely OA., Alastruey-Izquierdo A., Arenz D., Chen SC., Dannaoui E., Hochhegger B., et al. Mucormycosis, E. C. M. M. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medica, Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *The Lancet Infectious Diseases* 2019;19; e405-e421.
5. Aslan Ş., Omar I, Durak VA., Çıkrıklar Hİ., Özdemir F. Rhinocerebral Mucormycosis Case in the Emergency Room. *Journal of Emergency Medicine Case Reports* 2020;12; 106-107.
6. Avatef FM., Rezaei L., Javadirad E., Iranfar K., Khosravi A., Amini SJ., et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study. *Mycoses* 2021;64; 1366-1377.
7. Gangneux JP, Bougnoux ME., Dannaoui E., Cornet M., Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. *Journal de Mycologie Medicale* 2020;30; 100971.
8. Rawson TM., Moore LS., Zhu N., Ranganathan N., Skolimowska K., Gilchrist, M., et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing., *Clinical Infectious Diseases* 2020;71; 2459-2468.
9. Ahmadika K, Hashemi SJ., Khodavaisy S., Getso MI., Alijani N., Badali H., et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. *Mycoses*, 2021;64; 798-808.
10. Uğurlu ŞK., Selim S., Kopar A., Songu M. Rhino-orbital mucormycosis: clinical findings and treatment outcomes of four cases. *Turkish Journal of Ophthalmology* 2015;45; 169.